Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Company Overview

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.16 to $0.39
• 52-Week Range: N/A
• Volume: 1.27 million shs
• Average Volume: 160,047 shs
• Market Capitalization: $10.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.50
• Consensus Rating: Buy

Medicenna Therapeutics Stock Analysis - MarketRank™

Medicenna Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 805th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Medicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Medicenna Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MDNA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicenna Therapeutics does not currently pay a dividend.

Dividend Growth

Medicenna Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MDNA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.38% of the stock of Medicenna Therapeutics is held by institutions.

MDNA Stock Analysis - Frequently Asked Questions

How were Medicenna Therapeutics' earnings last quarter?

Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03.

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), e.l.f. Beauty (ELF), Meta Platforms (META), Arista Networks (ANET) and AppLovin (APP).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 8/11/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MDNA
• CIK: 1807983
• Web: www.medicenna.com
• Phone: (416) 648-5555
• Fax: 416-572-7501
• Employees: 16
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medicenna Therapeutics: $2.50
• High Price Target: $2.50
• Low Price Target: $2.50
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -42.68%
• Return on Assets: -35.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.57
• Quick Ratio: 9.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.32 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 69,637,000
• Free Float: 46,587,000
• Market Cap: $10.93 million
• Optionable: Not Optionable
• Beta: 1.30